Management of Essential Tremor prioritizes functional improvement over symptom elimination, and protocols begin with ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

CHICAGO, Ill. – Approximately 7 million Americans live with the movement disorder known as essential tremor. Another 1 million have Parkinson’s. But a new incision-less treatment that focuses ...

Shares is Praxis Precision Medicines rose in premarket trading Friday after it said it expects to submit to U.S. regulators a new drug application next year for its investigational drug to treat ...

Essential tremor (ET) is a common movement disorder affecting about 2% of the American population, and more than 20% of those over 90 years old. Despite its prevalence and decades of study, ...

HONOLULU — New imaging data may explain how transcutaneous afferent patterned stimulation (TAPS), a noninvasive, wearable therapy, works in patients with essential tremor (ET). In a small study that ...

February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

Researchers have identified a neurochemical signature that sets Parkinson's disease apart from essential tremor - two of the most common movement disorders, but each linked to distinct changes in the ...